Payment overview · 2025
General Payments
$1,483.66
68 reported records · 17 companies
Healthcare provider profile · identity verified
John O. Marsh, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MIDDLEBROOK, VA · NPI 1619997566
Verified facts
What the public records show
CMS Open Payments records show John O. Marsh, M.D. received $1,483.66 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $293.86 | 19.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $239.96 | 16.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $163.14 | 11.0% | 10 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $154.45 | 10.4% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $140.16 | 9.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.58 | 5.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.44 | 5.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.86 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.27 | 4.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.68 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.81 | 3.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.33 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.35 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.02 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.41 | 1.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.05 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.29 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,476.31 | 67 |
| Education | $7.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $239.96 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $155.57 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $154.45 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.24 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.65 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.01 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $85.41 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.58 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.58 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.39 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.39 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $69.39 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.86 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.86 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.27 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.83 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.13 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $53.84 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.74 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.81 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.90 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 30 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 224 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
224 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 907 | 260 |
| Levothyroxine Sodium | Levothyroxine Sodium | 707 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 179 |
| Pantoprazole Sodium | Pantoprazole Sodium | 558 | 149 |
| Losartan Potassium | Losartan Potassium | 506 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 494 | 154 |
| Tamsulosin Hcl | Tamsulosin Hcl | 446 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 118 |
| Omeprazole | Omeprazole | 338 | 85 |
| Potassium Chloride | Potassium Chloride | 325 | 91 |
| Furosemide | Furosemide | 319 | 102 |
| Lisinopril | Lisinopril | 315 | 84 |
| Celecoxib | Celecoxib | 311 | 90 |
| Gabapentin | Gabapentin | 296 | 83 |
| Metformin Hcl Er | Metformin Hcl | 283 | 79 |
| Metformin Hcl | Metformin Hcl | 282 | 76 |
| Famotidine | Famotidine | 276 | 82 |
| Alprazolam | Alprazolam | 272 | 52 |
| Meloxicam | Meloxicam | 238 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 41 |
| Eliquis | Apixaban | 224 | 55 |
| Trazodone Hcl | Trazodone Hcl | 224 | 66 |
| Montelukast Sodium | Montelukast Sodium | 222 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 52 |
| Sertraline Hcl | Sertraline Hcl | 218 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 211 | 56 |
| Prednisone | Prednisone | 209 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 59 |
| Finasteride | Finasteride | 191 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 190 | 53 |
| Pregabalin | Pregabalin | 182 | 43 |
| Tramadol Hcl | Tramadol Hcl | 174 | 52 |
| Allopurinol | Allopurinol | 173 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 47 |
| Buspirone Hcl | Buspirone Hcl | 167 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 41 |
| Carvedilol | Carvedilol | 160 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 156 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 29 |
| Ezetimibe | Ezetimibe | 139 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 123 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 32 |
| Valsartan | Valsartan | 110 | 33 |
| Farxiga | Dapagliflozin Propanediol | 109 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 107 | 25 |
| Jardiance | Empagliflozin | 105 | 22 |
| Mirtazapine | Mirtazapine | 104 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | 21 |
| Bumetanide | Bumetanide | 99 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 39 |
| Synthroid | Levothyroxine Sodium | 94 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 31 |
| Glimepiride | Glimepiride | 92 | 27 |
| Spironolactone | Spironolactone | 91 | 38 |
| Fentanyl | Fentanyl | 89 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 21 |
| Xarelto | Rivaroxaban | 78 | 21 |
| Levetiracetam | Levetiracetam | 76 | 15 |
| Ozempic | Semaglutide | 76 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 22 |
| Diazepam | Diazepam | 74 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 22 |
| Fluconazole | Fluconazole | 72 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 49 |
| Simvastatin | Simvastatin | 70 | 15 |
| Bupropion Xl | Bupropion Hcl | 68 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 35 |
| Azithromycin | Azithromycin | 65 | 56 |
| Clonazepam | Clonazepam | 65 | 15 |
| Lorazepam | Lorazepam | 64 | 29 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 63 | 62 |
| Warfarin Sodium | Warfarin Sodium | 63 | 18 |
| Baclofen | Baclofen | 60 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 18 |
| Hydromorphone Hcl | Hydromorphone Hcl | 58 | suppressed |
| Cephalexin | Cephalexin | 57 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 14 |
| Ondansetron Odt | Ondansetron | 56 | 22 |
| Cefdinir | Cefdinir | 55 | 48 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 17 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 50 |
| Amoxicillin | Amoxicillin | 51 | 32 |
| Digoxin | Digoxin | 50 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 41 |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Nitroglycerin | Nitroglycerin | 47 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Temazepam | Temazepam | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 12 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 28 |
| Atenolol | Atenolol | 37 | 11 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Nystatin | Nystatin | 37 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 36 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Klor-Con M20 | Potassium Chloride | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Methadone Hcl | Methadone Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 15 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Dexamethasone | Dexamethasone | 26 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Glipizide | Glipizide | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Verquvo | Vericiguat | 24 | suppressed |
| Metronidazole | Metronidazole | 23 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,483.66 · 68 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, Extended Holter, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, LEQVIO, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VERQUVO, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error